Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies - Wikidata - awgldk - TriplyDB

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

http://www.wikidata.org/entity/Q34997720

about

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes MDS prognostic scoring systems – past, present, and future Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results.Molecular genetic testing and the future of clinical genomics.Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia Microarray-based genomic profiling and in situ hybridization on fibrotic bone marrow biopsies for the identification of numerical chromosomal abnormalities in myelodysplastic syndrome.Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?Age-related somatic structural changes in the nuclear genome of human blood cells.Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling.Molecular pathogenesis of myelodysplastic syndromes.Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.Genome-wide arrays in routine diagnostics of hematological malignancies.Emerging immunosuppressive drugs in myelodysplastic syndromes.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?The role of high-throughput technologies in clinical cancer genomics.

P2860

Q26752940-548C088D-EE8D-4B95-90FC-9AA2418912D3 Q28082460-C779FC22-CFFB-4326-970F-1DC0DBD0BFCA Q28385687-5D27A3F6-B932-4E2E-8C01-4A6C05407064 Q28390558-77A69207-067D-4A6C-9EFA-5CA0929B896E Q28392579-8B9B3780-8D7B-463A-97EF-0E7C5A2E8766 Q33398180-C3E2C03F-8990-498E-A462-430F0669A2F6 Q33405487-BE8281B4-34D4-4287-A9F4-06DFA46541E0 Q33428604-3437EAF9-5D1C-410A-863D-AD0B9563F060 Q33695906-A0B4F6D6-EE9A-49A9-B1BE-D1FF71269E8D Q33829778-ECAE15F3-D6CF-4942-8B2F-0192429527E3 Q34013786-2F37D793-58E9-42F1-8BA4-B78ECCE27427 Q34049017-49DCA6C9-9930-4563-A552-0A2B01504598 Q34109454-C6C1764F-73C5-4BC0-B080-6DAC95B46D5F Q34345162-A794E33D-0573-40D9-885E-FC852962624A Q34667249-0A4A8BD2-D2AA-4624-8B09-D3D6DC927129 Q35083258-BD927B02-8FF2-48EF-BC23-7C6260E03B45 Q35346433-FA2965B6-4E38-451E-8A18-C39522AFDE7B Q35562821-993660C3-2161-4477-ADAF-8ABAB1578D7B Q35659186-25A9FDC8-F7BB-4B46-9921-5B8ED5EB6A40 Q35661305-AA37B69B-C801-430D-8D33-3B2D80592490 Q35748382-CF29ED3D-E3F6-4FDF-99F5-99B729FD0488 Q35985807-68F937D2-2954-4B08-B566-9EE5C604932B Q36163825-0AC11CAD-FDC9-42F8-9758-834066BA7D8C Q36266642-E3029457-497F-47C5-A615-1908E14F09C1 Q36290615-7A5827D8-4C38-4155-AD34-C702EBB8D0BB Q36612675-3B2368C6-0A9D-45BB-BC45-47892CC45590 Q36708989-2096A344-3D44-4419-9A0D-DF707BED9654 Q36876853-E48E920A-9D51-4B53-AA52-EAA74A551A7C Q36959939-BB031EAA-C886-4D8A-9AC4-199CD1C73896 Q37263146-AB97837F-32FC-49C5-872B-9D27CE003733 Q37349392-25CF7679-A208-4D4A-8B47-B9CA9FD743D6 Q37431973-B2CB165B-1380-4A53-BF7A-3437A41887A1 Q37528942-FE720643-6F74-4F92-9397-9A90C88425D7 Q37724602-B1B9424A-18FE-497C-B5FE-70174A91B924 Q37999070-7A73DFC5-9FD0-4CEA-A3C6-07F654C2DA67 Q38001406-0E93C9A5-625C-407F-89EC-F1CB19206E9E Q38060835-A8AE5AC8-3592-4642-AB4A-AEE0A8B9E6E3 Q38061848-70AB31CA-0D02-4A7B-A130-D3C33D27716C Q38078427-83AB09DA-03CB-4ABA-8781-554CDE3425C2 Q38088010-7D8C4FCF-B59B-4EFB-ABE5-6EB21F81CF62

P2860

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

http://www.wikidata.org/entity/Q34997720

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic impact of SNP array ...... d related myeloid malignancies

@ast

Prognostic impact of SNP array ...... d related myeloid malignancies

@en

Prognostic impact of SNP array ...... d related myeloid malignancies

@nl

type

label

Prognostic impact of SNP array ...... d related myeloid malignancies

@ast

Prognostic impact of SNP array ...... d related myeloid malignancies

@en

Prognostic impact of SNP array ...... d related myeloid malignancies

@nl

prefLabel

Prognostic impact of SNP array ...... d related myeloid malignancies

@ast

Prognostic impact of SNP array ...... d related myeloid malignancies

@en

Prognostic impact of SNP array ...... d related myeloid malignancies

@nl

P1433

Q34997720-45422C9D-FB66-432C-B4E2-912BBE6381B0

P1476

Q34997720-4E20F7A5-3D11-414B-B8FE-E8A127861079

P2093

Q34997720-0E8044F3-833F-422B-BB6D-0CE0CC940994

Q34997720-148C0F5C-6531-4601-B8CA-82E73298270C

Q34997720-24A6177C-8482-4049-BA40-C0958856E3D4

Q34997720-47D2D92F-A596-45FB-BCE5-7AA1E6DFAFD4

Q34997720-8142D361-3D17-46AD-9612-446AC9A701B0

Q34997720-828A2EE9-2F60-4BCF-BA8B-49837315C6AE

Q34997720-89B0FBBE-3478-41D8-8C7D-229AD01D9C9F

Q34997720-8D076BF0-5A51-4C7B-8F2C-08D8A6336E3F

Q34997720-9A813341-E809-4BF6-B623-12D2DD1ADAA0

Q34997720-A5999E3C-D867-4072-9B40-041E4B0EAC9F

P2860

Q34997720-0365AA66-AF39-4F04-8D55-0BDC93C7A61A

Q34997720-0748A477-0265-4D18-9F50-8CBB4C82705E

Q34997720-0E6B82EE-8DB5-4CD4-ADBB-A898B8F7FCE9

Q34997720-1D15CFA6-A042-4220-BC53-3284F82F2299

Q34997720-2F413A0A-BEC1-4931-9D86-8F873F88C71C

Q34997720-37C7B07B-B680-40D2-B81F-EAEC83DE44EB

Q34997720-3CD0F003-6477-40CB-ABDF-0634D92DA8FF

Q34997720-5D953F30-5851-4747-B663-BC048F5A7E5A

Q34997720-5DC173C3-FED5-412A-B54C-D80E64B84048

Q34997720-70889DF1-CE76-40FC-B5E3-757E9F54749D

P304

Q34997720-CCD811DD-2396-48A7-8368-B35BE53D56BE

P31

Q34997720-104DDDAE-D0B6-4FBF-A347-2A58A83AE642

P356

Q34997720-1B108142-0012-4BDB-95CF-E9E0989D0832

P407

Q34997720-4C8CB64A-B71B-4C2F-8FDF-9EADAF706ECA

P433

Q34997720-F145DA24-B5D3-41AA-8A14-042C76358C40

P478

Q34997720-B98635DB-B035-4D7C-8875-519575AF6562

P50

Q34997720-362CDC87-CCEE-4FE7-97D7-D21B235D0E44

P577

Q34997720-55AB4A11-A057-4C0B-A136-EE56C58D161D

P5875

Q34997720-F4F8C89C-97B9-4A8B-B651-3BA8B73DDDAA

P698

Q34997720-56D0B094-FDB7-4E11-BED6-094E3FFFAF92

P921

Q34997720-4F6FD474-5CFA-47E8-BFCF-47ECC83B39FB

P932

Q34997720-8C5FC66E-B074-4A95-A6B6-CFCF7FFF1379

P356

BLOOD-2010-07-295857

P1433

P1476

Prognostic impact of SNP array ...... d related myeloid malignancies

@en

P2093

Anjali S Advani

http://www.w3.org/2001/XMLSchema#string

Austin Kulasekararaj

http://www.w3.org/2001/XMLSchema#string

Azim Mohamedali

http://www.w3.org/2001/XMLSchema#string

Christine L O'Keefe

http://www.w3.org/2001/XMLSchema#string

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Jungwon Huh

http://www.w3.org/2001/XMLSchema#string

Lukasz P Gondek

http://www.w3.org/2001/XMLSchema#string

Michael A McDevitt

http://www.w3.org/2001/XMLSchema#string

Mikkael A Sekeres

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

Detection of large-scale variation in the human genome

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

Large-scale copy number polymorphism in the human genome

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

International scoring system for evaluating prognosis in myelodysplastic syndromes

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

P304

4552-4560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-07-295857

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49802345

http://www.w3.org/2001/XMLSchema#string

P698

21285439

http://www.w3.org/2001/XMLSchema#string

P921

P932

3099573

http://www.w3.org/2001/XMLSchema#string